Asher Biotherapeutics embarked on a search for a contract development and manufacturing organization (CDMO) that could handle Phase 2 and 3 production and commercial supply of its novel cis-targeted immunotherapies. It’s two lead candidates were in the investigational new drug (IND) enabling stage and Phase 1 respectively. Having been with another provider for early development, there was now the need to transfer to an outsourcing partner capable of late-phase work. A looming question was whether the relationship would be transparent and if there would be robust communication between a large CDMO and a small biotech.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center